Atara Biotherapeutics 미래 성장

Future 기준 확인 1/6

Atara Biotherapeutics은 연간 수입과 매출이 각각 43.6%와 17.6% 증가할 것으로 예상되고 EPS는 연간 43.6%만큼 증가할 것으로 예상됩니다.

주요 정보

43.6%

수익 성장률

43.6%

EPS 성장률

Biotechs 수익 성장	27.2%
매출 성장률	17.6%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	28 Jan 2025

최근 미래 성장 업데이트

Recent updates

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 21

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Jan 16

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Jan 07

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Jul 21

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 03

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

수익 및 매출 성장 예측

NasdaqGS:ATRA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	178	9	-77	-62	3
12/31/2026	71	-100	-44	-54	5
12/31/2025	73	-89	-53	-91	6
12/31/2024	113	-98	-55	-34	5
9/30/2024	100	-133	-95	-95	N/A
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	-241	-236	N/A
9/30/2019	N/A	-292	-242	-234	N/A
6/30/2019	N/A	-279	-241	-230	N/A
3/31/2019	N/A	-256	-232	-215	N/A
12/31/2018	N/A	-231	-216	-180	N/A
9/30/2018	N/A	-186	-189	-147	N/A
6/30/2018	N/A	-159	N/A	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A
6/30/2015	N/A	-41	N/A	-22	N/A
3/31/2015	N/A	-30	N/A	-20	N/A
12/31/2014	N/A	-28	N/A	-17	N/A
9/30/2014	N/A	-21	N/A	-14	N/A
6/30/2014	N/A	-18	N/A	-12	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ATRA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ATRA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ATRA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ATRA 의 수익(연간 17.6% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: ATRA 의 수익(연간 17.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ATRA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/31 02:18
장 마감 주가	2025/01/31 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Atara Biotherapeutics, Inc. 15 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Jonathan Miller	Evercore ISI

Atara Biotherapeutics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 365%

Forecast to breakeven in 2027

Consensus revenue estimates increase by 14%

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Price target decreased by 71% to US$30.33

Recent updates

Consensus EPS estimates fall by 365%

Atara Biotherapeutics, Inc. Provides Update on Clinical Programs Related to Ebvallo™? (Tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

New major risk - Share price stability

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

New major risk - Shareholder dilution

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2027

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

New major risk - Share price stability

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Price target decreased by 71% to US$30.33

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock